We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-21.21%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$45.4M
AUM Growth
+$3.55M
Cap. Flow
+$3.85M
Cap. Flow %
8.47%
Top 10 Hldgs %
72.25%
Holding
50
New
3
Increased
9
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$13.3M
2
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$3.63M
3
BLUE
bluebird bio
BLUE
+$93.6K
4
EXEL icon
Exelixis
EXEL
+$92.2K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$58.1K

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$3.68M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$2.42M
3
LITS
Lite Strategy Inc
LITS
+$1.55M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$1.14M
5
ADMS
Adamas Pharmaceuticals
ADMS
+$891K

Sector Composition

Rank Sector Weight
1 Healthcare 50.42%
2 Miscellaneous 49.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IQV icon
26
IQVIA
IQV
$43.1B
$307K 0.68%
2,643
-513
-16% -$62.1K
CRL icon
27
Charles River Laboratories
CRL
$13.3B
$302K 0.66%
2,665
-161
-6% -$20.2K
UTHR icon
28
United Therapeutics
UTHR
$21.3B
$290K 0.64%
2,664
-141
-5% -$16.3K
GILD icon
29
Gilead Sciences
GILD
$182B
$289K 0.64%
4,618
+85
+2% +$5.94K
BLUE
30
DELISTED
bluebird bio
BLUE
$271K 0.6%
211
+61
+41% +$93.6K
TECH icon
31
Bio-Techne
TECH
$11.3B
$255K 0.56%
7,048
-1,920
-21% -$80.2K
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.74B
$241K 0.53%
14,899
-5,929
-28% -$115K
AGIO icon
33
Agios Pharmaceuticals
AGIO
$2.01B
$236K 0.52%
5,115
-9,987
-66% -$616K
RARE icon
34
Ultragenyx Pharmaceutical
RARE
$1.34B
$232K 0.51%
5,339
-795
-13% -$43.5K
ALKS icon
35
Alkermes
ALKS
$7.69B
$224K 0.49%
7,605
-17,637
-70% -$650K
NBIX icon
36
Neurocrine Biosciences
NBIX
$16B
$213K 0.47%
2,986
-405
-12% -$38.8K
CKPT
37
DELISTED
Checkpoint Therapeutics
CKPT
$205K 0.45%
11,276
– –
FBIO icon
38
Fortress Biotech
FBIO
$84.4M
$201K 0.44%
15,602
– –
PGEN icon
39
Precigen
PGEN
$2.45B
$177K 0.39%
27,109
+3,329
+14% +$37.3K
SCTL
40
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$81K 0.18%
12,659
– –
AKBA icon
41
Akebia Therapeutics
AKBA
$267M
– –
-45,004
Closed -$397K
AXSM icon
42
Axsome Therapeutics
AXSM
$11.6B
– –
-120,150
Closed -$415K
LITS
43
Lite Strategy Inc
LITS
$37.8M
– –
-18,000
Closed -$1.55M
SCYX icon
44
SCYNEXIS
SCYX
$45.8M
– –
-375
Closed -$36K
PRTK
45
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-18,000
Closed -$175K
CLVS
46
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-82,430
Closed -$2.42M
ADMS
47
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-44,500
Closed -$891K
CFRX
48
DELISTED
ContraFect Corporation
CFRX
– –
-84
Closed -$140K
ACHN
49
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-308,569
Closed -$1.14M
TSRO
50
DELISTED
TESARO, Inc.
TSRO
– –
-94,300
Closed -$3.68M
1
2

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2018 Portfolio in Review

As of Q4 2018, Opus Point Partners Management held 50 positions worth $45.4M, up 8.5% from $41.9M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Opus Point Partners Management deployed $3.85M of net new capital in Q4 2018, opening 3 new positions and adding to 9 existing holdings. Its largest new stake was iShares Biotechnology ETF: 125,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Alkermes, an estimated $650K trimmed.

  • Opus Point Partners Management's largest Q4 2018 buy was iShares Biotechnology ETF: 125,000 shares worth $12.1M.
  • Opus Point Partners Management added most to bluebird bio in Q4 2018, an estimated $93.6K increase.
  • Opus Point Partners Management's biggest Q4 2018 reduction was Alkermes, cutting an estimated $650K.
  • Opus Point Partners Management fully exited TESARO, Inc. in Q4 2018, selling an estimated $3.68M.
  • Opus Point Partners Management's ten largest holdings make up 72% of its $45.4M portfolio in Q4 2018.
  • Opus Point Partners Management opened 3 new positions and closed 10 in Q4 2018.
  • Opus Point Partners Management's portfolio value rose 8.5% quarter-over-quarter to $45.4M.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.